Clinical trial NCT04655352: Safety and Tolerability of Bacillus Subtilis MB40 in Healthy Adult Volunteers
Official title: Single Center, Clinical Trial Examining the Safety and Tolerability of a Bacillus Subtilis Probiotic in Healthy Adult Volunteers in a Single-Blind Design
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Participants
Lead sponsor: BIO-CAT, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Prism Research LLC
First posted: 2020-12-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Human volunteers meeting eligibility criteria listed above.

Brief summary: This study is a single-blind, placebo-lead in design examining the safety and tolerability of a probiotic, Bacillus subtilis MB40. Subjects received a 7-day placebo BID lead-in and a 21-day BID course of Bacillus subtilis MB40. GI questionnaires and Bristol stool charts along with evaluation of any medically significant changes, based on physical examination findings, clinical laboratory tests and vital signs assessments were used to determine the safety and tolerability of MB40.


Eligibility criteria: Inclusion Criteria:

1. Normal, healthy adult volunteers aged 18 to 55 years.
2. BMI of 18 to 32 kg/m2 (inclusive)
3. Have no clinically significant findings on screening evaluations (clinical, laboratory)
4. If female, participant is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) OR

   Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
   * Hormonal contraceptives (stable for 1 month) including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
   * Double-barrier method
   * Intrauterine devices
   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
   * Vasectomy of partner (shown successful as per appropriate follow-up)
5. Able to comprehend and willing to sign an Informed Consent Form (ICF).

Exclusion Criteria:

1. History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders.
2. Current or recent history (\<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection.
3. Frequent GERD, indigestion, nausea, or vomiting (1 or more days per week).
4. Frequent abdominal pain/cramps or bloating (1 or more days per week).
5. Frequent constipation, diarrhea, or alternating constipation/diarrhea (1 or more days per week).
6. Abdominal pain before bowel movements that is relieved with defecation (most bowel movements).
7. Abdominal complaints often worsened by worry or tension (1 or more days per week).
8. Medical diagnosis of esophagitis, gastritis, ulcers, inflammatory bowel disease, gastrointestinal cancer, celiac disease, or irritable bowel syndrome.
9. Recent gastrointestinal bleeding (hematemesis, hematochezia, melena in past 3 months) or anemia in the past 3 months.
10. Unintentional weight loss of 10 lbs or more in the past 3 months.
11. Screening GI Questionnaire Score of ≥ 4 for any single item.
12. Current clinically significant viral infection
13. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin
14. Resting heart rate less than 45 bpm or greater than 100 bpm.
15. History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure \>150/90 mm Hg)
16. History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed.
17. Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis)
18. History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations.
19. Use of any tobacco-containing or nicotine-containing products (including cigarette, pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum) more frequently than 50 cigarettes per week within 2 months prior to Screening or \> 20 per week from screen through the end of the study
20. Current treatment or treatment within 30 days or 5 half-lives (t ½) prior to the first dose of study product with another investigational product or current enrollment in another investigational drug protocol at the time of screening.
21. Use of any over-the-counter, prescription, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations), within 7 days prior to study entry, unless deemed acceptable by the Investigator.
22. Use of greater that 2 units per day of alcohol-containing or caffeine-containing foods or beverages within 72 hours prior to study entry and throughout the duration of the study.
23. Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma within 2 weeks prior to Screening.
24. Receipt of blood products within 3 months prior to study entry.
25. Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations.

Primary outcomes:
measure: Occurrence of adverse events
timeFrame: 4 weeks
Secondary outcomes:
measure: Weekly mean of daily frequency of GI symptoms
timeFrame: 4 weeks
measure: Weekly mean of daily severity of GI symptoms
timeFrame: 4 weeks
Other outcomes:
measure: Frequency of bowel movements
timeFrame: 4 weeks
measure: Incidence of clinically significant abnormal vital signs
timeFrame: Screening and day 29
measure: Incidence of clinically significant abnormal complete blood panel
timeFrame: Screening and day 29
Locations:
Study officials:
affiliation: Prism Research LLC
name: Mark Matson, MD
role: STUDY_DIRECTOR
References:
citation: Spears JL, Kramer R, Nikiforov AI, Rihner MO, Lambert EA. Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements. Nutrients. 2021 Feb 25;13(3):733. doi: 10.3390/nu13030733.